achat cialis belgique 
comprar levitra generico en andorra 
achat de viagra 
levitra medicament 
viagra natural para mujeres recetas 
tenovate cream price india obagi tretinoin cheap synthroid prescription assistance program buy aciclovir tablets online is there a generic equivalent for synthroid sildenafil vs tadalafil viagra vente libre belgique o que é tadalafil precio cialis 20 en farmacia dynafil vs viagra revia cheap order can you buy propranolol over the counter uk buy proscar no prescription online clomid for sale australia tadalis sx price acheter du cialis au quebec cialis vente libre belgique forum cialis online vendita italia cialis rezeptfrei schweiz farmacie che vendono viagra
priligy mg ligne générique pyridium effexor quand le prendre

New biomarker technique could provide early detection for cancer

Wed, May 19, 2010

Oral Cancer News

Author: press release provided by University of Connecticut

Modern genetic testing can predict your risk of contracting particular diseases based on predispositions discovered in your DNA. But what if similar biotechnology could tell you that you’ve got a disease before you notice any symptoms? What if it could even tell you, before any signs of a tumor, that you have cancer?

Jim Rusling, professor of chemistry at UConn and professor of cell biology at the UConn Health Center, ponders these questions on a daily basis. Since 2006, he and colleagues at the University and the National Institutes of Health (NIH) have been developing techniques to detect biomarker proteins – the physiological traits that indicate that a person has a specific disease – for prostate and oral cancer. Because these biomarkers are often present in the blood in a disease’s early stages, they can be used for early detection and prevention.

“DNA predicts which proteins can be made, but it can’t predict which proteins are actively expressed,” Rusling says. “It only assesses the risk of a disease. There’s a big push now to measure proteins as biomarkers.”

In a recent publication in the journal Analytical Chemistry, Rusling and his colleagues describe a system they developed to detect with record sensitivity the bloodstream levels of a protein associated with several types of oral cancer, including head and neck squamous cell carcinomas. The project was funded by a $1.5 million grant from the National Institute of Environmental Health Sciences at NIH.

The protein, called interleukin-6 or IL-6, is normally present in very low levels in the bloodstream – so low that previous biomarker sensors might not be able to detect it. This and other biomarkers are signaling molecules, which can instruct cells that have become cancerous to grow faster. Their levels can increase even before tumors begin to form, enabling early detection that might head off the formation of cancerous growths.

Print Friendly
Be Sociable, Share!
, , , , , ,

Leave a Reply

You must be logged in to post a comment.